

Party A:
Falcon Surgical Co. (Pvt) Ltd with SRN PK-
MF-000018125 and located in Wazirabad Road,
Village Golophala, Sialkot 51310, Pakistan
(Hereinafter referred to as "COMPANY").

Party B:
CMC Medical Devices & Drugs SL with SRN
ES-AR-000000293 and located in C/
Horacio Lengo 18, 29006, Málaga, Spain.
(Hereinafter referred to as "CMC").

1 INTRODUCTION:

This contractual agreement/mandate has been written in accordance with the applicable provisions defined in Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Regulation 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Regulations 90/385/EEC and 93/42/EEC ('MDR') and Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU ('IVDR') ('Regulations'), if applicable, to specify the relationship between two parties mentioned above.

Both parties have agreed as follows regarding the handling of all products (hereinafter called "Products") manufactured by COMPANY and sold to the European Economic Area ('EEA') and Turkey.

2 DESIGNATION AND ACCEPTANCE OF THE MANDATE

- 2.1 COMPANY is a manufacturer of medical devices and/or in vitro diagnostic medical devices not established in a Member State of the European Union, such devices may only be placed on the Union market if the manufacturer designates a sole Authorised Representative for one specific generic device group in accordance with article 11(1 and 2) and defined as in article 2(32) MDR or article 11(1 and 2) and 2(25) IVDR.
- 2.2 COMPANY hereby designates CMC as Authorised Representative, who accepts such designation, as an Authorised Representative for the Business Area and Products set out in Appendix C of this agreement, for placing products on the market. Only Products listed in Appendix C will be subject to the mandate of the Authorised Representative.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

2.3 The responsibility of both parties is as stated hereafter in this agreement in relation to the devices that it covers. Appendix A provides an overview of responsibilities. In event of a conflict, the provisions of this agreement shall take precedence over the responsibilities listed in Appendix A, since Appendix A is mainly attached for COMPANY's convenience.

2.4 CMC does not act as an importer or distributor as defined in the MDR/IVDR. Parties explicitly agree that CMC shall not undertake any tasks or responsibilities with respect to the Products listed in Appendix C that would make CMC qualify as an importer or distributor in the meaning of article 13 or 14 MDR or IVDR.

3 VALIDITY OF THE AGREEMENT

3.1 This agreement will enter into effect from (see 'Effective Date' date in Appendix C) provided that the agreement is signed by both parties, payment for the service is received and on the condition that COMPANY has made available to CMC a copy of the liability insurance required according to clause 8 of this agreement. The agreement remains effective until the "Agreement Expiration Date" stated underneath the header of this document.

3.2 Any changes to this agreement must be approved in writing by CMC and COMPANY by signing a new version of the agreement.

3.3 The service term for each Product starts from the moment the agreement enters into force, and remains effective until the termination of this agreement. Products that need to be added to the list in Appendix C after the moment the agreement entered into force, will be added by means of an addendum signed by both parties. The COMPANY warrants that the Products listed in Appendix C comprise generic device groups.

4 TERMINATION OF AGREEMENT

4.1 This agreement expires at the "Agreement Expiration Date" stated underneath the header of this document, unless terminated by either party with a prior written notification period of sixty (60) days. This agreement is subject to renewal by signing a new version of the agreement with the new agreed expiration date.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

- 4.2 Either party may terminate this agreement upon written notice in the event the other party is in material breach of any obligation under this agreement that is not cured within ten (10) working-days after the breaching party has been notified in writing of the breach and the other party's intent to terminate the agreement.
- 4.3 In the situation where COMPANY acts contrary to its obligations under the MDR/IVDR, CMC is obligated to terminate this agreement in accordance with article 11(3)(h) MDR/IVDR. Upon becoming aware of such a regulatory non-compliance, CMC will provide written notice to the COMPANY. COMPANY shall answer within three (3) working days and by either i) confirming that it is indeed acting contrary to its obligations under the MDR/IVDR, or ii) explain why its acting is accordance with the MDR/IVDR. When parties disagree on whether COMPANY acts contrary to its obligations under the MDR/IVDR, CMC is entitled to terminate the agreement immediately.
- 4.4 In the event that liability coverage required by COMPANY in accordance with clause 8 of this agreement, becomes invalid, terminated or is withdrawn and this insurance issue is not fixed within five (5) days, CMC may terminate the agreement forthwith without further notice.

Upon termination of this agreement:

- 4.5 COMPANY will not place on the market any products bearing the name and address of CMC on its labelling. To this end, COMPANY shall remove all references to CMC from packaging, products, labelling, instructions for use, declaration of conformity and any other marketing material where these details might appear.
- 4.6 In case of termination in accordance with paragraph 4.3. of this agreement CMC will notify the Spanish Competent Authorities and COMPANY's Notified Body that CMC shall no longer act as the Authorised Representative of COMPANY.

In the event of a change of Authorised Representative, CMC will cooperate with the incoming Authorised Representative in accordance with article 12 MDR/IVDR. The detailed arrangements for a change of Authorised Representative shall be clearly defined in an agreement between COMPANY, CMC, and the incoming Authorised Representative.

5 TASKS TO BE PERFORMED BY CMC ON BEHALF OF COMPANY

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

- 5.1 CMC shall comply with requirements imposed on “Authorised Representative” in article 11 of the MDR/IVDR and perform the following tasks:
- i. Verify that the EU Declaration of Conformity and technical documentation have been drawn up and, where applicable, that an appropriate conformity assessment procedure has been carried out by COMPANY;
 - ii. Keep a copy of the technical documentation, the EU Declaration of Conformity and, if applicable, a copy of any relevant certificate, including any amendments and supplements, issued in accordance with article 56 MDR / article 51 IVDR, available for the Competent Authorities for a period of at least 10 years after the last device covered by the EU Declaration of Conformity has been placed on the market. In the case of implantable devices, the period shall be at least 15 years after the last device has been placed on the market;
 - iii. Comply with the registration obligations laid down in article 31 of the MDR and article 28 of IVDR and verify that COMPANY has complied with the registration obligations laid down in articles 27 and 29 MDR and articles 24 and 26 IVDR;
 - iv. In response to a request from a Competent Authority, provide that the Competent Authority with all the information and documentation necessary to demonstrate the conformity of a device, in an official Union language determined by the Member State concerned;
 - v. Forward to COMPANY any request by a Competent Authority of the Member State in which the Authorised Representative has its registered place of business for samples, or access to a device and verify that the Competent Authority receives the samples or is given access to the device;
 - vi. Cooperate with the Competent Authorities on any preventive or corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by the devices;
 - vii. Immediately inform the COMPANY about complaints and reports from healthcare professionals, patients and users about suspected incidents related to a Product listed in Appendix C of this agreement;

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

viii. Terminate this agreement if COMPANY acts contrary to its obligations under the MDR or IVDR.

5.2 By way of derogation from clause 5.1, for Products that are covered by the transitional regime of article 120(3) MDR/110(3) IVDR, the so-called 'legacy devices', not all provisions set out in article 5.1 apply. Generally, the requirements of the Council Directive 93/42/EEC of 14 June 1993 concerning medical devices ('MDD')/Directive 90/385/EEC of 20 June 1990 concerning active implantable medical devices ('AIMDD')/Directive 98/79/EC of 27 October 1998 concerning in vitro diagnostic ('IVDD') apply to these legacy devices. However, in line with MDCG 2021-25 guidance*/MDCG 2022-8 guidance**: conformity with the MDR/IVDR article 11(3) (c) - (g) of the MDR/IVDR is required, reflected under point 5.1(iii) - (vii) of this agreement. Additionally, article 11(7) MDR/IVDR applies to legacy devices. This means that for legacy devices, the elements described under 5.1(i) - (ii) and 5.1(viii) do not form part of the mandate to CMC unless explicitly otherwise.

*Medical Device Coordination Group, 2021-25 guidance: 'Regulation (EU) 2017/745 - application of MDR requirements to 'legacy devices' and to devices placed on the market prior to 26 May 2021 in accordance with Directives 90/385/EEC or 93/42/EEC', October 2021.

**Medical Device Coordination Group, 2022-8 guidance: 'Regulation (EU) 2017/746 - application of IVDR requirements to 'legacy devices' and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC, May 2022

5.3 Except in cases of legacy devices mentioned in the previous paragraph, CMC shall provide copies of all correspondence related to the tasks described in paragraph 5.1 to the Person Responsible of Regulatory Compliance (PRRC), indicated by COMPANY in Appendix B. COMPANY must therefore have available within their organization at least one person responsible for regulatory compliance who possesses the requisite qualifications in the field of medical devices set out in article 15 MDR / IVDR.

5.4 Except in cases of legacy devices mentioned in the paragraph 5.2. of this agreement, CMC will have permanently and continuously available one person responsible for regulatory compliance (PRRC) who possesses the requisite expertise regarding the regulatory requirements for medical devices in the Union, indicated also in Appendix B.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

5.5 CMC will allow the use of its name and address from the Effective Date on for the use with the draft Declaration of Conformity (DoC) and draft device label for the Notified Body conformity assessment application, if applicable. The use of the name of address of CMC will be allowed upon the COMPANY having complied with all applicable requirements in particular the registration obligations, ensuring permanent access to the Declaration of Conformity, technical documentation and, if applicable, a copy of the relevant certificate, and upon the positive outcome of the above verification activities that CMC is mandated to perform on the behalf of the Company which is confirmed.

5.6 Upon request of the Competent Authority, CMC will provide it with a copy of this agreement.

5.7 The communication between CMC and the COMPANY shall be in the English language. Communication or documentation in any other language may be refused by CMC or CMC may charge the COMPANY a reasonable market standard service fee for translation of documents.

6 OBLIGATIONS OF THE COMPANY REGARDING THE AUTHORISED REPRESENTATIVE MANDATE

COMPANY shall enable CMC to perform the tasks described under clause 5 of this agreement.

6.1 For clause 5.1(i) – (ii): the COMPANY agrees under article 10(8) MDR/ 10(7) IVDR to provide permanent access to an up-to-date version of the technical documentation to CMC as long as this agreement is in place, and ensures that provided information is true and accurate.

The COMPANY agrees to only place devices on the Union Market after CMC has confirmed verification with the requirements of article 11 MDR/IVDR and after CMC has confirmed that it is able to keep the described documentation available.

6.2 COMPANY shall comply with all the requirements specified in article 10 MDR and article 10 IVDR regarding general obligations of manufacturers. COMPANY warrants that the Products are in conformity with the provision of the MDR/IVDR by affixing the CE marking and including them in CMC's mandate.

6.3 COMPANY shall affix CMC's name and registered address as COMPANY's Authorised Representative on the labels, instructions for use and Declaration of Conformity of the Products listed in Appendix C. The COMPANY shall ensure that the CMC address will only be used in accordance with the requirements of the MDR/IVDR, and not for other purposes.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

- 6.4 For clause 5.1 (iii): COMPANY is required under article 10(7) MDR / 10(6) IVDR to comply with the obligations relating to the UDI system referred to in article 27 MDR / 24 IVDR and with the registration obligations referred to in articles 29 and 31 MDR / 26 and 28 IVDR. COMPANY will inform CMC right after it has met these registration requirements. Only after CMC has confirmed to COMPANY that it has verified the registration, COMPANY is allowed to place its Products on the EEA market.
- 6.5 For clause 5.1 (iv): COMPANY is required under article 10(14) MDR / 10(13) IVDR to provide a Competent Authority all the information and documentation necessary to demonstrate the conformity of the device, in an official Union language determined by the Member State.
- 6.6 For clause 5.1 (v): COMPANY is required under article 10(14) MDR / 10(13) IVDR to provide to the Competent Authority of CMC samples of the device free of charge or, where that is not possible, provide access to the device in any other way.
- 6.7 For clause 5.1 (vi): COMPANY is required under article 10(14) MDR / 10(13) IVDR to cooperate with a Competent Authority, at its request, on any corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by devices which they have placed on the market or put into service. In this light, COMPANY will on its own turn cooperate with the Competent Authority and additionally, support CMC in case assistance is requested by CMC.
- 6.8 For clause 5.1 (vii): COMPANY provides CMC confirmation of receipt immediately whenever it has received the complaints and reports from healthcare professionals, patients and users about suspected incidents that have been forwarded by CMC.
- 6.9 For clause 5.1 (viii): in case of termination of the agreement due to COMPANY acting contrary to its regulatory obligations under the MDR/IVDR, COMPANY agrees to accept the termination of the agreement. COMPANY agrees that CMC shall not be liable for contractual or extra-contractual damages resulting from termination of the agreement for this reason.
- 6.10 According to article 87 MDR and 82 IVDR COMPANY will supply CMC with the relevant information relating to: surveillance procedures, adverse incident notifications, safety corrective actions, devices registration and any other information that allows CMC to cooperate with Market surveillance authorities.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

- 6.11 COMPANY should keep, for all Products listed in Appendix C, the relevant documents in English for at least ten (10) years after the last device has been placed on the market, or in the case of implantable devices, fifteen (15) years the last device has been placed on the market in the EEA in order to be provided to CMC for the purpose to be forwarded to or inspected by the Competent Authority.
- 6.12 COMPANY should provide CMC with the sales list of Products of last calendar quarter through email to CMC's PRRC before the 10th day of the following months: January, April, July and October. Such duty of the COMPANY will not be waived even though there are no sales in one trimester, therefore COMPANY will provide a declaration of no sales to CMC.

7 VIGILANCE IN EUDAMED

Complaints/Incident Reports/Field Safety Corrective Actions

The parties agree that the Vigilance in Eudamed will not be mandated to CMC. COMPANY will report by itselfs serious incidents and Field Safety Corrective Actions (FSCA) involving its Products to the relevant Competent Authority via EUDAMED or the national relevant system. CMC will provide assistance to COMPANY. The PRRC contact persons of each party will be used for communication in relation to such incidents or FSCA.

COMPANY shall keep a register of any received incidents/complaints/non-conforming products and provide CMC with any information upon their request.

8 LIABILITY

- 8.1 COMPANY will add CMC as an additional insured to its product liability insurance policy on behalf of CMC to cover CMC for potential exposure under this agreement in the proper fulfilment of the duties of CMC, except that the COMPANY need not insure and not protect CMC from liability that results from gross negligence of wrongful acts, omissions or unauthorized activities by CMC which are not performed in favor or objective interest of the COMPANY or results from a substantial breach of this agreement by CMC.
- 8.2 The COMPANY will provide this additional insured policy before signing this agreement and will continue to do so each subsequent year for the duration of this agreement. Provided that COMPANY fails to fulfil this obligation, COMPANY shall indemnify and hold CMC harmless from any damages, losses, and fines incurred to CMC derived from third parties claims.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

8.3 COMPANY's product liability insurance shall cover bodily injury, property damage and loss suffered by users, patients or others caused by a Product manufactured by COMPANY and sold in the Union. The insurance coverage will be proportionate to the risk class, type of device and the size of the COMPANY in accordance with article 10 (16) MDR / 10 (15) IVDR. The insurance shall be in place to provide sufficient financial coverage in respect to the COMPANY's potential liability under Directive 85/374/EEC, without prejudice to more protective measures under national law (article 10(16) MDR / 10 (15) IVDR). Proof of maintaining this insurance and proof that such insurance covers CMC and the Products listed in Appendix C for the EEA market and meets the standards set out in article 10(16) MDR / 10(15) IVDR must be provided to CMC before the signature of this agreement. All insurance coverage provided to CMC shall be maintained by COMPANY for the duration of this agreement, including a run-off coverage to cover all Products manufacturer by COMPANY and sold in the Union for the duration of the agreement and thereafter for as long as these Products bear the name and address of CMC.

8.4 Where the COMPANY conducts clinical investigations in the Union the COMPANY shall be responsible for obtaining and maintaining the insurance coverage prescribed by law.

8.5 The COMPANY shall indemnify, defend and hold CMC, its directors, officers, and employees free and harmless from all claims or liabilities for bodily injury, property damage infringement of third party's right concerning intellectual property (i.e. but not limited to copy right, patent right or competition right) arising or alleged to be arising out of the activities, services or other involvement of Company with respect to any sale or delivery of devices of the COMPANY and resulting from, caused by or alleged to be caused by such devices and shall bear all costs and expenses (excluding attorney's fees incurred by CMC before the assumption of defense by the COMPANY) of defending such claims if the cause of any such action had been a defect already existing or alleged to be existing under European or national binding law at the moment when the device left the control of the COMPANY. This commitment on the part of the COMPANY will be maintained upon conclusion/termination of this agreement and for as long as claims can still be raised against CMC due to activities performed by CMC in the fulfillment by CMC of the terms of this agreement.

9 REMUNERATION

9.1 The COMPANY agrees to remunerate CMC the amount stated underneath the header of this document (Fee:) for fulfilling its role as the designated sole Authorised Representative. The first remuneration is due on the Effective Date as described in clause 3 of this agreement.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

- 9.2 Bank charges or transaction fees must be covered 100% by the COMPANY. The COMPANY will ensure that all payments are remitted in their totality to the beneficiary.
- 9.3 Both parties agree that the remuneration does not include fees and/or taxes imposed by European and/or national Competent Authorities. CMC shall not be responsible for the delivery of the certificates or other documentation, samples or other things and all delivery charges shall be fully paid by the COMPANY.
- 9.4 Additional services including but not limited to free sales certificates, GMDN codes, adding new products to this agreements, technical file reviews, can be provided with separate charges, to be agreed between the parties.
- 9.5 The payment of the remuneration will be transferred within ten (10) business days upon receipt of each invoice.
- 9.6 Invoices will be sent in electronic format (PDF) and will reference a purchase order.
- 9.7 In case COMPANY terminates the agreement at any time no refund shall be made and COMPANY is not entitled to offset any payments due under this agreement against alleged claims. The full remuneration of the following year will be applicable in case the termination by COMPANY is given to CMC within the 60 days prior to the annual renewal date.
- 9.8 The COMPANY agrees to remunerate CMC at a rate of three hundred fifty Euro (€ 350) per hour, following the cancellation of this agreement solely for any activities which might occur during the transition period between CMC and its (potential) successor (transition period being that of the day the agreement ends and the final complaint stemming from the COMPANY's Products carrying the CMC address).
- 10 DISPUTES
- 10.1 Goodwill is the basis of resolving any disputes between parties.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

10.2 If any dispute or claim between parties is brought before the court, each party consents to exclusive jurisdiction and venue in the Spanish Courts. The place of fulfilment and domicile is the domicile of CMC.

11 CONFIDENTIALITY

11.1 COMPANY and CMC shall treat with confidentiality any information and document, in any form, disclosed in writing or orally, including the agreement itself.

11.2 Either party will not disclose, in whole or in part, any information to any third party and will not duplicate or publish in any media any documentation received except upon mutual written consent.

11.3 This article will survive the termination of this agreement

12 Severability Clause

12.1 If any provision of this Agreement is held to be invalid or unenforceable under any applicable law or regulation, such provision shall be deemed modified to the extent necessary to make it valid and enforceable, and the remaining provisions of this Agreement shall remain in full force and effect.

12.2 The invalidity or unenforceability of any provision shall not affect the validity or enforceability of any other provision of this Agreement.

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Version	Change Description
V01	Renewal of agreement 1449231103.EC.v1. Signed on 16/12/2024

For: Falcon Surgical Co. (Pvt) Ltd

Authorized Signature name and position:

[Redacted Signature]

Adnan Hayat
CEO

Date: 16/12/2024

For: CMC Medical Devices & Drugs S.L.

Authorized Signature name and position:

Manuel Mateos
Regulatory Affairs Manager

Date: 16/12/2024

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR



APPENDIX A of the Agreement N° 1449241210.EC.v1

Summary of responsibilities for convenience purpose:

Responsibility	COMPANY	CMC
"COMPANY" shall be responsible for the content of instruction (user's) manuals and shall ensure that English language instruction manuals are available to CMC. "COMPANY" shall ensure that the required local language instruction manuals are provided to the customers.	Yes	No
"COMPANY" shall, in order to allow CMC to fulfil its tasks, ensure that CMC has the necessary documentation permanently available.	Yes	No
Comply with the registration obligations "regarding registration of COMPANY, Authorised Representative and importer" and verify that "COMPANY" has complied with the registration obligations regarding "Unique Device Identification System & Registration of Devices".	Yes	Yes
Cooperate with the Competent Authorities on any preventive or corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by devices.	Yes	Yes

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Responsibility	COMPANY	CMC
Cooperating with the regulatory authority and providing it with any information it requires during market surveillance activities.	Yes	Yes
Ensuring that all distributors, importers or responsible for handling "COMPANY" products inside the EU, on note that CMC is the Authorised Representative of "COMPANY" in the EU and they must pursue on event or negative effect for their products.	Yes	No
Ensuring that CMC is the Authorised Representative in EU on labelling of "COMPANY" products, and its name and head office are correctly written.	Yes	No
Forward to "COMPANY" any request by a Competent Authority of the Member State in which CMC has its registered place of business for samples, or access to a device and verify that the Competent Authority receives the samples or is given access to the device.	No	Yes
Immediately inform "COMPANY" and regulatory authority about complaints and reports from healthcare professionals, patients and users about suspected incidents related to a device for which they have been designated.	No	Yes
In response to a request from a Competent Authority, provide that Competent Authority with all information and documentation necessary to demonstrate the conformity of a device, in an official Union language determined by the Member State concerned.	Yes	Yes
Inform "the Competent Authority and the notified body" in case of the termination of this mandate and the reason for termination.	No	Yes

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Responsibility	COMPANY	CMC
Keep available a copy of the technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate, including any amendments and supplements at the disposal of Competent Authorities for a period of at least 10 years after the last device covered by the EU declaration of conformity has been placed on the market. In the case of implantable devices, if any, the period shall be at least 15 years after the last device has been placed on the market.	Yes	Yes
Notification of any changes to the necessary information (technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate, including any amendments and supplements)	Yes	No
Notification of technical changes to the necessary information (technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate, including any amendments and supplements)	Yes	No
Provide a copy of this agreement (mandate) to the Competent Authority, upon request.	No	Yes
Provides the regulatory authority with information on its place of business, the name and position of a responsible person and the "COMPANY" it represents.	No	Yes
Providing the regulatory authority with the information it requires when "COMPANY" seeks authorization to market its devices.	No	Yes
Terminate the mandate if "COMPANY" acts contrary to its obligations under EU Regulation.	No	Yes
Verify that the EU declaration of conformity and technical documentation have been drawn up and, where applicable, that an appropriate conformity assessment procedure has been carried out by "COMPANY".	Yes	Yes

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

APPENDIX B of the Agreement N° 1449241210.EC.v1

PRRC information:

COMPANY:

Name: Muhammad Usman

Qualification: MBA

Email: usmanhayat.falcon@gmail.com

CMC:

Name: Manuel Mateos

Qualification: Bachelor's degree in pharmacy

Email: info@cmcmmedicaldevices.com

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

APPENDIX C of the Agreement N° 1449241210.EC.v1

Authorized Representative's Business Area:
EEA + Turkey markets

Effective date: 16/11/2024

Expiration date: 15/11/2025

Products covered:

Product Name	Model (M:) // Ref (R:)	BASIC UDI DI	CLASS	REGULATION	Date
Periodontal Probes	R:	++G120PPROBE3N	Class I	MDR 2017/745	16 dic. 2024
Abdominal Retractors	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Accessory	R:	(++G120AccessoryXH)	Class I	MDR 2017/745	21 nov. 2023
Articulators	R:	(++G120ArticulatorsF7)	Class I	MDR 2017/745	21 nov. 2023
Band Pusher	R:	(+ +G120BandPusherNU)	Class I	MDR 2017/745	21 nov. 2023
Biopsy Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Curettes	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Cutters	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Cutting Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone files / rasps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Holding Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Levers/elevator	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Punches	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Saws	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Bone Spoons	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Chin Retractor	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Chisels, Gouges	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Clamp manipulation forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Clamps	R:	(++G120ClampsJS)	Class I	MDR 2017/745	21 nov. 2023
Crocodile forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Crown Remover	R:	(+ +G120CrownRemoverD M)	Class I	MDR 2017/745	21 nov. 2023
Curettes	R:		Class I	MDD 93/42/EEC	14 dic. 2022

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Product Name	Model (M:) // Ref (R:)	BASIC UDI DI	CLASS	REGULATION	Date
Dental Examination Kit	R:	(+ +G120DentalExaminati o5W)	Class I	MDR 2017/745	21 nov. 2023
Dental excavators	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dental Files	R:	(++G120DentalFiles2L)	Class I	MDR 2017/745	21 nov. 2023
Dental files / rasp	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dental knives	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dental osteotomes	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dental rongeurs	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dental surgical scissors	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dental Syringes	R:	(+ +G120DentalSyringesX A)	Class I	MDR 2017/745	21 nov. 2023
Diagnostics	R:	(++G120DiagnosticsCS)	Class I	MDR 2017/745	21 nov. 2023
Disimpaction Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dissecting forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Dissector	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Elevators	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Explorers	R:	(++G120ExplorersM6)	Class I	MDR 2017/745	21 nov. 2023
Filling Instruments	R:	(+ +G120FillingInstrument RP)	Class I	MDR 2017/745	21 nov. 2023
Fixation Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Forceps	R:	(++G120ForcepsY2)	Class I	MDR 2017/745	21 nov. 2023
Gall Stone forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Grinding Tools	R:	(+ +G120GrindingTools4Q)	Class I	MDR 2017/745	21 nov. 2023
Hand Drills	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Holloware	R:	(++G120HollowareFF)	Class I	MDR 2017/745	21 nov. 2023
Hooks	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Impression Tray	R:	(+ +G120ImpressionTray W)	Class I	MDR 2017/745	14 dic. 2022
Intestinal Clamps	R:		Class I	MDD 93/42/EEC	14 dic. 2022

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Product Name	Model (M:) // Ref (R:)	BASIC UDI DI	CLASS	REGULATION	Date
Intestinal grasping forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Kidney Stone Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Ligature Tools	R:	(+ +G120LigatureTools6X)	Class I	MDR 2017/745	21 nov. 2023
Mallets	R:	(++G120MalletsWC)	Class I	MDR 2017/745	21 nov. 2023
Matrix Retainers	R:	(+ +G120MatrixRetainers UB)	Class I	MDR 2017/745	21 nov. 2023
Mouth Mirror & Handles	R:	(+ +G120MouthMirrorHan dleHY)	Class I	MDR 2017/745	21 nov. 2023
Nasal Chisels	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Nasal files / Rasps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Nasal gouge	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Needle holders	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Needle Holders	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Orthopaedic Rongeurs	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Osteotomes	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Periosteal elevators	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Periotomes	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Pliers	R:	(++G120PliersQR)	Class I	MDR 2017/745	21 nov. 2023
Probes	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Retractors	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Retractors	R:	(++G120RetractorsLL)	Class I	MDR 2017/745	21 nov. 2023
Retractors	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Rhinoplasty Knives	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Rib Shears	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Rib Spreaders	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Root elevators	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Rubber Dam	R:	(++G120RubberDam7F)	Class I	MDR 2017/745	21 nov. 2023
Scalpel handles	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Scalpels	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Scalpels & Knives	R:		Class I	MDD 93/42/EEC	14 dic. 2022

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Product Name	Model (M:) // Ref (R:)	BASIC UDI DI	CLASS	REGULATION	Date
Scissors	R:	(++G120ScissorsRE)	Class I	MDR 2017/745	21 nov. 2023
Scissors	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Self-Retaining Retractor	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Septum Elevators	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Skin hook	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Spatulas	R:	(+G120SpatulasTS)	Class I	MDR 2017/745	21 nov. 2023
Spatulas	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Spoons	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Surgical Bulldog Clamps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Suture Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Tonsil Dissector	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Tonsil Knives	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Tonsil Snares	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Tooth extraction forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Tracheal Hooks	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Trocars	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Tweezers	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Umbilical cord scissors	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Universal Saw	R:	(+ +G120UniversalSawVK)	Class I	MDR 2017/745	21 nov. 2023
Uterine Curettes	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Uterine Scoops	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Uterine tenaculum Forceps	R:		Class I	MDD 93/42/EEC	14 dic. 2022
Wire Saws	R:		Class I	MDD 93/42/EEC	14 dic. 2022

Agreement Expiration Date:
15th of November 2025

Fee: 900,00 EUR

Products: 99

The products listed in this Appendix C are included under the agreement 1449241210.EC.v1 starting from the date in column <Date>.

Products added before the 01/October/2022 will not state the starting date but the comment <See corresponding contract>.

Unless stated otherwise in the column <Date>, the Products will remain included in the contract until the expiration date of this agreement (15 nov. 2025).

For: Falcon Surgical Co. (Pvt) Ltd

For: CMC Medical Devices & Drugs S.L.

Authorized Signature name and position:

Adnan Hayat
CEO

Auth
Man
Regu

Date: 16/12/2024

Date: 16/12/2024

Please use this link to fill appendix D and sign this agreement

Please use the link of the Appendix E to upload the Technica Documentation.